Voxelotor (Oxbryta) has received accelerated approval to treat sickle cell disease in children ages four to 11 years. This is a new indication for the drug.Voxelotor prevents red blood cells from forming a sickle shape, reducing the damage to tissues and red blood cells that is common with sickle cell disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.NAJ.0000827312.29859.99 | DOI Listing |
Publication Analysis
Top Keywords
sickle cell
12
children ages
8
cell disease
8
red blood
8
blood cells
8
sickle
4
cell drug
4
drug approved
4
approved children
4
ages voxelotor
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!